Prevalence of prostate cancer in the Seventh Region of Chile

被引:0
作者
Baechler, R [1 ]
Henríquez, R [1 ]
Aqueveque, X [1 ]
Martínez, ME [1 ]
Soto, A [1 ]
机构
[1] Hosp Reg Talca, Serv Salud Maule, Dept Programas Personas, Talca, Chile
关键词
carcinoma in situ; prostate - specific antigen; prostatic neoplasms;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: In 1998, there were 1,218 deaths in Chile caused by prostate cancer. This figure results in a death rate of 16.6 per 100,000 males for this disease. Aim: To assess the prevalence of prostate cancer in the Seventh Region of Chile. Material and methods: A probabilistic sample of 327 males aged 40 to 59 years old was studied. In all, a codified questionnaire was applied, a digital rectal examination was performed and a blood sample was drawn to measure prostate specific antigen. All digital rectal examinations were performed by the same observer. Patients with an abnormal rectal examination or prostate specific antigen were subjected to a prostatic biopsy under ultrasound guidance. Results: In 14 subjects, the digital rectal examination was considered abnormal and in seven, prostate specific antigen was over 4 ng/ml. All subjects with elevated prostate specific antigen had an abnormal rectal examination. In three of the 14 subjects, the biopsy showed a well differentiated adenocarcinoma. All three were aged over 50 years old. The resulting calculated prevalence of prostate cancer was 9.2 per 1,000 males (CI 4.2-14.1). Conclusions: the cost effectiveness of screening for early diagnosis of prostate cancer must be calculated, to decide its incorporation in preventive medical examinations (Rev Med Chile 2001; 129: 1305-10).
引用
收藏
页码:1305 / 1310
页数:6
相关论文
共 50 条
  • [41] Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation
    Albertsen, PC
    Hanley, JA
    Penson, DF
    Fine, J
    JOURNAL OF UROLOGY, 2004, 171 (06) : 2221 - 2225
  • [42] Evaluation of Prostate Specific Antigen Acceleration for Prostate Cancer Diagnosis
    Benecchi, Luigi
    Pieri, Anna Maria
    Pastizzaro, Carmelo Destro
    Potenzoni, Michele
    JOURNAL OF UROLOGY, 2011, 185 (03) : 821 - 826
  • [43] Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer
    McNeel, DG
    Nguyen, LD
    Storer, BE
    Vessella, R
    Lange, PH
    Disis, ML
    JOURNAL OF UROLOGY, 2000, 164 (05) : 1825 - 1829
  • [44] Obesity, serum prostate specific antigen and prostate size: Implications for prostate cancer detection
    Freedland, SJ
    Platz, EA
    Presti, JC
    Aronson, WJ
    Amling, CL
    Kane, CJ
    Terris, MK
    JOURNAL OF UROLOGY, 2006, 175 (02) : 500 - 504
  • [45] The distribution of serum prostate-specific antigen levels among American men: Implications for prostate cancer prevalence and screening
    Porter, Michael P.
    Stanford, Janet L.
    Lange, Paul H.
    PROSTATE, 2006, 66 (10) : 1044 - 1051
  • [46] Prostate-specific Antigen-Based Prostate Cancer Screening: Reduction of Prostate Cancer Mortality After Correction for Nonattendance and Contamination in the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer
    Bokhorst, Leonard P.
    Bangma, Chris H.
    van Leenders, Geert J. L. H.
    Lous, Jan J.
    Moss, Sue M.
    Schroder, Fritz H.
    Roobol, Monique J.
    EUROPEAN UROLOGY, 2014, 65 (02) : 329 - 336
  • [47] THE EFFECTIVENESS OF PROSTATE SPECIFIC ANTIGEN DENSITY IN PREDICTING PROSTATE CANCER AND CLINICALLY SIGNIFICANT PROSTATE CANCER IN PATIENTS AGED 70 YEARS AND OVER
    Avci, Sinan
    Caglayan, Voikan
    Onen, Efe
    Kilic, Metin
    Gul, Abdullah
    Oner, Sedat
    TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGISI, 2020, 23 (02): : 197 - 205
  • [48] Prevalence and patterns of the use of complementary therapies among prostate cancer patients: An epidemiological analysis
    Nam, RK
    Fleshner, N
    Rakovitch, E
    Klotz, L
    Trachtenberg, J
    Choo, R
    Morton, G
    Danjoux, C
    JOURNAL OF UROLOGY, 1999, 161 (05) : 1521 - 1524
  • [49] Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer
    D'Amico, AV
    Moul, J
    Carroll, PR
    Sun, L
    Lubeck, D
    Chen, MH
    JOURNAL OF UROLOGY, 2005, 173 (05) : 1572 - 1576
  • [50] Linkage between Polymorphisms in the prostate specific antigen AREI gene region, prostate cancer risk, and circulating tumor cells
    Medeiros, R
    Morais, A
    Vasconcelos, A
    Costa, S
    Pinto, D
    Oliveira, J
    Carvalho, R
    Lopes, C
    PROSTATE, 2002, 53 (01) : 88 - 94